-
Mashup Score: 0
An abstract is unavailable.
Source: journals.lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Purpose To assess caregivers’ characteristics and influence of the presence or absence of the caregiver on clinical outcomes of older (≥70 years) metastatic castration-resistant prostate cancer (mCRPC) patients treated with abiraterone (ABI) or enzalutamide (ENZ). Methods Patients from the Meet-URO 5 ADHERE study were assessed with a 5-item caregiver evaluation questionnaire focusing on the…
Source: SpringerLinkCategories: Latest Headlines, Oncologists2Tweet-
Patients with #prostatecancer needing caregiver are more vulnerable with lower G8 #gerionc score and worse outcomes with oral #enzalutamide or #abiraterone #meeturo #IUCS23 Room for vulnerability identification and support @urologysummit @ProstateUKProfs https://t.co/vUhPi3Pdwq https://t.co/qMPK2MBg0f
-
-
Mashup Score: 3FDA Approves Olaparib Triplet for mCRPC - 11 month(s) ago
Findings from the phase 3 PROpel have led to the FDA approval of olaparib in combination with abiraterone and prednisone or prednisolone for a prostate cancer subgroup.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
BREAKING: The #FDA has approved #olaparib in combination with #abiraterone and #prednisone or #prednisolone for adult patients with #mCRPC. #pcsm | @DukeCancer @FDAOncology https://t.co/1Yc2JZjrER https://t.co/W7r5Qs1bKr
-
-
Mashup Score: 0Wolters Kluwer Health - 1 year(s) ago
JavaScript Error JavaScript has been disabled on your browser. You must enable it to continue. Here’s how to enable JavaScript in the following browsers: Internet Explorer From the Tools menu, select Options Click the Content tab Select Enable JavaScript Firefox From the Tools…
Source: lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Adding #olaparib to standard-of-care #abiraterone shows a trend toward improvement in overall #survival by more than 7 months in the treatment of metastatic castrate-resistant #prostatecancer, according to final OS results of the #PROpel trial: https://t.co/tuGD7Thn6c #mCRPC https://t.co/FaRRAKY2NP
-
-
Mashup Score: 0Wolters Kluwer Health - 1 year(s) ago
JavaScript Error JavaScript has been disabled on your browser. You must enable it to continue. Here’s how to enable JavaScript in the following browsers: Internet Explorer From the Tools menu, select Options Click the Content tab Select Enable JavaScript Firefox From the Tools…
Source: lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Adding #olaparib to standard-of-care #abiraterone shows a trend toward improvement in overall #survival by more than 7 months in the treatment of metastatic castrate-resistant #prostatecancer, according to final OS results of the #PROpel trial: https://t.co/tuGD7Thn6c #mCRPC https://t.co/uJEo6q0e04
-
-
Mashup Score: 0Wolters Kluwer Health - 1 year(s) ago
JavaScript Error JavaScript has been disabled on your browser. You must enable it to continue. Here’s how to enable JavaScript in the following browsers: Internet Explorer From the Tools menu, select Options Click the Content tab Select Enable JavaScript Firefox From the Tools…
Source: lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Adding #olaparib to standard-of-care #abiraterone shows a trend toward improvement in overall #survival by more than 7 months in the treatment of metastatic castrate-resistant #prostatecancer, according to final OS results of the #PROpel trial: https://t.co/tuGD7ThUVK #mCRPC https://t.co/SLwq0HcGJ9
-
-
Mashup Score: 0
Data from the second interim analysis of the phase 3 MAGNITUDE study showed that the addition of niraparib to abiraterone acetate and prednisone prolonged survival for patients with metastatic castration-resistant prostate cancer with BRCA mutations.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
An #NDA has been submitted to the #FDA seeking the approval of #niraparib in combination with #abiraterone acetate and prednisone for patients with BRCA+ #mCRPC. #pcsm https://t.co/eLZDSXleza
-
-
Mashup Score: 0
Findings from the second interim analysis of the phase 3 MAGNITUDE study showed the positive benefit of niraparib plus abiraterone and prednisone in metastatic castration-resistant prostate cancer.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
In the second interim analysis of the phase 3 MAGNITUDE study, there was a positive benefit with #niraparib plus #abiraterone and #prednisone in metastatic castration-resistant prostate cancer. #mpcrc #pcsm #GU23 | @ASCO https://t.co/Pdz2IzeaX4
-
-
Mashup Score: 0FDA Delays PDUFA Hearing for Olaparib/Abiraterone Combo in mCRPC - 1 year(s) ago
The FDA has told AstraZeneca and MSD that the agency will extend the Prescription Drug User Fee Act date by 3 months to provide further time for a full review of the supplementary new drug application for olaparib plus abiraterone and prednisone or prednisolone for patients with mCRPC.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
ICYMI: @US_FDA has told AstraZeneca and MSD that the agency will extend the PDUFA date by 3 months to provide further time for a full review of the sNDA for #olaparib plus #abiraterone and #prednisone or prednisolone for patients with mCRPC. #pcsm https://t.co/rw2T9AuOHU
-
-
Mashup Score: 1FDA Delays PDUFA Hearing for Olaparib/Abiraterone Combo in mCRPC - 1 year(s) ago
The FDA has told AstraZeneca and MSD that the agency will extend the Prescription Drug User Fee Act date by 3 months to provide further time for a full review of the supplementary new drug application for olaparib plus abiraterone and prednisone or prednisolone for patients with mCRPC.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
ICYMI: @US_FDA has told AstraZeneca and MSD that the agency will extend the PDUFA date by 3 months to provide further time for a full review of the sNDA for #olaparib plus #abiraterone and #prednisone or prednisolone for patients with mCRPC. #pcsm https://t.co/9f47Gh5gP8 https://t.co/LoltwruJTv
-
Researchers demonstrated that a combination of inhibitor drugs slowed the growth of human-sampled #prostatecancer cells in mice resistant to the most common anti-testosterone therapy, #abiraterone. Read more: https://t.co/Hyud7m1Tny https://t.co/YWUdCuLMcV